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Abstract
DTI -015 (BCNU in 100% ethanol ) utilizes solvent -
facilitated perfusion for the intratumoral treatment of
gliomas. The water-miscible organic solvent vehicle,
ethanol, facilitates a rapid and thorough saturation of
the tumor with the dissolved anticancer agent, BCNU.
Rats bearing established intracranial T9 gliosarcoma
tumors received no treatment (group 1), a single intra-
tumoral injection of ethanol vehicle (group 2) or DTI-015
(5 mg/kg BCNU) (group 3), or a single intratumoral in-
jection of DTI-015 followed by systemicBCNU (group 4).
Ethanol alone (n=13) had no effect on survival; MST=17
days compared to 18 days for untreated controls (n=35).
DTI-015 (n=45) produced an ILS of 417% (MST=93) and
472% (MST=103) when combined with systemic BCNU
(n=14). Overall, 24 of 59 rats receiving DTI-015 were
judged to be cured, with 20 living a normal life span of
600 to 700 days, and 4 rats sacrificed healthy at 121, 135,
307, and 384 days post DTI-015 with no evidence of
viable T9 tumor. Histology demonstrated that DTI-015
totally eradicated the T9 tumors in animals living a
normal life span. The results demonstrate that a single
injection of DTI-015 produces a 40% cure rate in rats
bearing established intracranial T9 tumors.
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Introduction
Intravenously administered BCNU (carmustine) has been
one of the leading chemotherapeutic agents used for treating
gliomas for approximately 30 years now [15,35]. Although
BCNU demonstrates a good activity against glioma cells in
vitro [16,17], its clinical efficacy is limited by both acute toxic
effects upon the bone marrow and gastrointestinal tract [7 ],
and delayed toxic effects upon the liver and lungs [8,23,33],
when administered intravenously.
Attempts have been made to achieve a higher tumor- to-
systemic exposure ratio by administering BCNU intra-
arterially into the vascular region subtending the tumor.
This approach for delivering BCNU, however, provides no
increase in survival [30], a less than four - fold tumor- to-
systemic exposure advantage [13,14], and results in unac-
ceptable eye [18,20] and neurological toxicity [22,24,28].
More recently, locally applied slow-release polymeric
implants (e.g., Gliadel1Wafer ) have been employed in order
to achieve a high tumor exposure to BCNU while minimizing
overall systemic exposure [3]. When used as an adjunct to
surgical resection for prolonging survival in patients with
recurrent glioblastoma multiforme, Gliadel1 demonstrates a
small but significant clinical patient benefit [4 ]. However, the
limitation of Gliadel1 and other depot approaches is that the
mechanism of drug movement into the tumor is by diffusion,
which restricts penetration distances to a few millimeters.
We have recently developed the technology of solvent-
facilitated perfusion (SFP) for the local / regional treatment of
solid tumors [5,9,25,32]. Instead of commonly used aqueous
delivery vehicles [1,19,21], SFP utilizes water -miscible or-
ganic solvent vehicles that move easily through both water
and membranes to drive the penetration of solubilized anti-
cancer drugs throughout tumors [26].
We now report on the efficacy of intratumorally adminis-
tered DTI-015, a solution of BCNU in the water -miscible
organic delivery solvent vehicle ethanol, in the rat T9 glio-
sarcoma intracranial tumor model.
Materials and Methods
Animals
Male CDF rats (Fischer 344; Taconic Farms, German-
town, NY), aged 60 to 80 days, were allowed to acclimate to
laboratory conditions for 1 to 2 weeks prior to studies. They
were given Purina rat chow and water ad libitum and main-
tained six per cage in a roomwith a light–dark cycle (12 hours
on, 12 hours off ). All experimental procedures were per-
formed between 9 A.M. and 7 P.M. At the time of tumor cell
implantation, the rats weighed between 120 and 240 g.
T9 Gliosarcoma Cells
T9 gliosarcoma cells were maintained in a monolayer
tissue culture in Falcon plastic flasks. Flasks contained
Eagle’s minimal essential medium (Gibco, Gaithersburg,
MD) supplemented with 20% newborn calf serum, nonessen-
tial amino acids, L-glutamine, and an antibiotic–antimycotic
solution containing penicillin, streptomycin, and amphotericin
B. The cultures were incubated at 378C in a high-humidity
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atmosphere containing 5% carbon dioxide. When cells
formed a monolayer and became confluent, they were trypsi-
nized (0.25% trypsin, 0.2% ethylenediaminetetraacetic
acid), and subcultured. Aliquots of cells from various passa-
ges were kept frozen in liquid nitrogen with 10 vol.% glycerin.
Intracerebral Tumor Implantation
T9 cells were trypsinized, harvested from their flasks,
and suspended in phosphate-buffered saline. Cells were
counted in a hemocytometer and viability was determined by
the trypan blue exclusion method. Immediately prior to
implantation, cells were drawn up into a Hamilton microliter
syringe (no. 702) equipped with a 25-gauge needle. Seven
hundred thousand tumor cells in a volume of 10 l were
injected stereotactically into the right caudate hemisphere
of each animal. For this tumor inoculation, animals were
anesthesized on day 0 with pentobarbital sodium (25–30
mg/kg) intraperitoneally and placed into a stereotactic
frame. The head was shaved, a midline longitudinal scalp
incision was made, and the bregma was identified. Using a
dental drill, a 1-mm burr hole was placed 3 mm to the right of
the bregma and 1 mm posterior to the coronal suture. Next,
the needle tip was lowered into the cerebrum to a depth of
5 mm below the dural surface and then retracted by 1 mm.
The purpose of this retraction procedure was to create a
small pocket into which the cells could be injected. The
needle bevel was positioned to face laterally in order to
mitigate against inadvertent intraventricular injection. Cells
were injected slowly over a period of 2 minutes. The needle
was then withdrawn and the burr hole was sealed with bone
wax. The operative field was cleaned with povidone iodine
solution and the scalp incision was closed with clips.
DTI-015
DTI-015 was prepared by dissolving 100 mg of BCNU
[(1,3-bis(2-chloroethyl ) -1-nitrosourea] (Bristol Laborato-
ries, Syracuse, NY) in 1.5 ml of absolute ethanol. All
intratumoral injections used this 66.7 mg/ml formulation
directly. The dose delivered to each animal was 5 mg/kg
body weight BCNU. Accordingly, a rat weighing 200 g
received 15 l, equivalent to a total dose of 1.0 mg of BCNU.
For animals additionally receiving 5 mg/kg body weight
BCNU intraperitoneally, this 66.7 mg/ml solution was further
diluted to 5 mg/ml with sterile water immediately preceding
its use. This is a relatively low dose, and approximates 40%
of the LD10 determined for intraperitoneal BCNU in rats
[33,34].
Intratumoral DTI-015 Injection
Rats were anesthesized with ether and pentobarbital
sodium (25–30 mg/kg) and placed into the stereotactic
frame. The clips and bone wax were carefully removed. DTI-
015 was injected directly into the tumor (at a flow rate of
7.5 l /min) through a Hamilton microsyringe set to the
same coordinates and using the same technique as in
the initial tumor implantation. As before, the operative field
was cleaned with povidone iodine solution and the scalp was
closed with clips.
Treatment
All animals received tumor implantation on day 0. Controls
(group 1) received no treatment; vehicle controls (group 2)
received a single intratumoral injection of absolute ethanol
on day 7. One experimental group (group 3) received a
single injection of intratumoral DTI-015 (BCNU dissolved in
absolute ethanol at a dose of 5 mg/kg body weight ) on day 7.
A second experimental group (group 4) received a single
intratumoral DTI-015 injection (BCNU dissolved in absolute
ethanol at a dose of 5 mg/kg body weight ) on day 7, followed
by a second dose of BCNU in aqueous solution (5 mg/kg
body weight ) delivered intraperitoneally on day 12.
Evaluation
Using length of survival as an endpoint, the efficacy of the
two therapeutic regimens was compared. All animals were
autopsied at their time of death. A gross inspection was
made of the lungs, liver, and kidneys, and the brain was
removed in toto and fixed in 10% buffered formalin for 3
days. A single coronal section was cut through the center of
the tumor site and both halves were embedded in paraffin,
serially sectioned, and stained with hematoxylin and eosin
for blind histopathologic examination. Animals classified as
cured were those that lived a normal life span, i.e., 600 to 700
days, and also four animals that were sacrificed healthy for
histology on days 121, 136, 307, and 384, and demonstrated
no observable viable T9 tumor.
Statistical Methods
Median survival rates were calculated for each group, and
the data were analyzed nonparametrically with the Wilcoxon
rank sum test.
Results
Survival
Operative mortality was 4.3% (4/93) for tumor-bearing
animals following sodium pentobarbital administration but
preceding intratumoral injection, 7.1% (1/14) following
intratumoral ethanol vehicle injection, and 5.1% (4/79)
following intratumoral DTI-015 injection. A subset of rats
receiving intratumoral DTI-015 was sacrificed for histology
on day 7 (n=2), day 10 (n=5), and day 14 (n=5), and was
not included in the overall survival analysis. Survival data are
summarized in Table 1.
Control animals (n=35) had a median survival of 18 days.
Ethanol vehicle controls (n=13) had a median survival of 17
days. One of the ethanol vehicle control animals lived a
normal life span, apparently healthy, and was euthanized for
histology on day 614.
Animals that received a single intratumoral injection of
DTI-015 (n=45) had a median survival of 93 days, i.e., an
increased life span of 417% (P<1106). Twenty of the 45
rats (44%) were judged to be cured, with 17 living a normal
life span and 3 animals sacrificed healthy at 121, 136, and
384 days posttreatment with no viable T9 tumor present.
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Animals that received a single intratumoral injection of
DTI-015 followed by intraperitoneal BCNU (n=14) lived a
median of 103 days, i.e., an increased life span of 472%
(P<1106 ). Four of the 14 rats (29%) were judged to be
cured, with three living a normal life span and one animal
sacrificed healthy at 307 days posttreatment with no viable
tumor present.
The addition of the intraperitoneal BCNU to the treatment
regimen did not statistically enhance the therapeutic benefit
of the primary intratumoral DTI-015. Considered as one
group, the 59 rats that received intratumoral DTI-015 lived a
median survival time of 96 days, i.e., an increase in life span
of 433% (P<1106). Twenty- four rats (41%) were judged
to be cured. Survival curves are shown in Figure 1.
Both control and vehicle- treated groups demonstrated
essentially one steep phase, with 90% of the animals dying
between days 9 and 24. In contrast, the DTI-015–treated
group demonstrated four phases: an initial steep phase in
which animals died between days 9 and 24; a second less
steep phase in which animals died between days 25 and 166;
a third shallow phase in which animals died between days
251 and 325; and a fourth phase in which animals lived a
normal life span.
Histopathology
Following implantation of tumor cells, the tumors some-
times appeared as single foci but often grew in multifocal
fashion demonstrating both upper and lower foci (Figure 2, A
and B ). The tumors were very healthy and densely cellular
with many mitoses. The average size of the tumor and the
fact that animals began dying as early as day 9 indicate the
severe therapeutic challenge posed by this model. Day 7
following tumor implantation was chosen for treatment.
Figure 2 demonstrates the tumor growth at 7, 9, and 17
days postimplantation.
If untreated, tumors grew within 12 to 24 days into very
large masses typically replacing an entire hemisphere in
cross section (Figure 2C ). The bulk of the tumors consisted
of viable and rapidly dividing cells, although small focal areas
of necrosis were occasionally observed.
Ethanol vehicle–treated controls also demonstrated
tumors occupying most of a hemisphere at death (Figure
3). However, small cysts were usually found — often
accompanied by necrosis, polymorphonuclear leukocytes,
and some hemorrhage — presumably marking the site of
injection. Apart from the small areas of necrosis, these
ethanol - treated tumors were indistinguishable in size and
viability from untreated control tumors. An exception was the
one ethanol - treated animal that lived a normal life span,
which demonstrated histology similar to the DTI-015–
treated animals that lived a normal life span as described
below.
DTI-015–treated animals that died during the first phase,
i.e., up to 24 days, displayed large, healthy tumors. However,
substantial tumor cell necrosis with cysts, polymorphonu-
clear leukocyte infiltration, and sometimes hemorrhage was
also observed usually at the top of the tumor, whereas the
bottom grew out aggressively.
Most DTI-015–treated animals that died during the
second phase (25–166 days posttreatment) displayed large
tumors containing prominent bands of central necrosis.
However, three animals that lived relatively long (94, 108,
and 98 days) did not. Two of these histologically presented
with acute hemorrhage and no tumor, while the third
displayed a large cyst with polymorphonuclear leukocytes
and some very unhealthy T9 tumor.
The DTI-015–treated animals that died during the third
phase (days 251–325) demonstrated cysts, necrosis, scar
tissue, and no viable T9 tumor. The cause(s) of death was
unknown.
DTI-015–treated animals that lived a normal life span
(600–700 days) displayed large cysts always surrounded by
Figure 1. Survival of rats with intracranial T9 gliosarcoma following either
intratumoral DTI - 015 (n=59 ), or ethanol vehicle ( n=13 ), or no treatment
( n=35 ).
Table 1. Effect of Intratumoral DTI - 015 on Survival.
Group Treatment n Median Survival
Time (days )
% ILS* Cures % Cures P y
1 Untreated control 35 18 0 0 0
2 Intratumoral ethanol 13 17 6 1 8 NS
3 Intratumoral DTI - 015 45 93 417 20z 44 <110 6
4 Intratumoral DTI - 015+ IP BCNU 14 103 472 4x 29 <110 6
5 Groups 3 and 4 59 96 433 24 41 <110 6
*Percent increase in life span= (median day of survival for treated groupmedian day of survival for control group /median day of survival for control group )100.
ySignificantly different from group 1 untreated controls as determined by the Wilcoxon rank sum test.
zIncludes three animals, apparently healthy, euthanized on days 121, 136, and 384 for histology; no viable T9 tumor was found histologically.
xIncludes one animal, apparently healthy, euthanized on day 307 for histology; no viable T9 tumor was found histologically.
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dense connective tissue capsules, some containing poly-
morphonuclear leukocytes (Figure 4, A–C ). Although no
viable T9 tumor was found, tumor cell necrosis was usually
present, as was hemosiderin pigment. Some animals also
presented with extensive infiltrates of lymphocytes and
plasma cells.
In order to study the acute effects of DTI-015, a group of
animals implanted with T9 gliosarcoma and treated with
intratumoral DTI-015 was sacrificed healthy on days 7, 10,
and 14 (n=2, 5, and 5, respectively, at each time point ), as
shown Figure 5. Histology demonstrated that these animals
could be placed into one of three groups. One group
displayed tumor destruction at the top, with the majority of
the tumor left untouched (Figure 5A ). In a second group,
most of the tumor was successfully treated, but small
amounts of viable tumor remained (Figure 5B ). In a third
group, the tumor was totally eradicated by the therapy and
was replaced with a cyst containing necrotic tumor tissues
(Figure 5C ).
Discussion
This study was undertaken to investigate the efficacy of a
single intratumoral injection of DTI-015 in established T9
gliosarcoma intracranial tumors. The results demonstrate
that DTI-015 is a highly effective treatment in this model,
producing an increase in life span in excess of 400% with
40% of the treated animals being cured.
The degree of efficacy obtained is striking considering the
aggressiveness of this tumor, the multifocal tumor growth
exhibited, the inability to precisely target the intratumoral
injection, and the otherwise poor efficacy of BCNU in T9. In
the latter regard, we previously demonstrated in this same
model that the equivalent BCNU dose administered systemi-
cally produced no significant efficacy and only a 57%
increase in life span when delivered intraarterially [6 ].
The lack of efficacy exhibited by the ethanol vehicle
administered alone is not surprising given that intratumoral
ethanol has never been demonstrated to be effective in brain
tumors and its well -known activity in primary liver tumors is
based upon the delivery of ethanol volumes in great excess
of the tumors being treated [31]. In contrast, the volume
of ethanol vehicle used to deliver BCNU in DTI-015 is a
fraction of the tumor volume (Bodell WJ, in preparation)
[2,9,11,12,25,32], estimated in the current study at 25% to
50% of the treated tumor volume. That the ethanol, however,
is necessary to deliver the solubilized BCNU throughout the
tumor effectively has been demonstrated in the subcuta-
neous Walker 256 model, where substitution of the ethanol
vehicle for an aqueous delivery vehicle results in loss of
efficacy [32].
The histology studies demonstrated that the direct intra-
tumoral treatment totally eradicated the tumors in rats that
lived a normal life span. A near total absence of normal
tissue necrosis was observed, suggesting that DTI-015
selectively eliminated the T9 tumors without producing
significant collateral damage to the surrounding normal
brain. Consistent with this finding, autoradiography studies
demonstrate that DTI-015 selectively perfuses high levels of
14C-BCNU throughout 9L intracranial tumors with minimal
penetration occurring into surrounding normal brain [26].
Recent pharmacokinetic studies also support these findings
demonstrating that DTI-015 produces a selective BCNU
exposure to the tumor that is two to three logs higher than
the exposure to normal brain and peripheral tissues, and
results in orders-of -magnitude increases in the efficacy/
safety ratio compared to intravenous BCNU [29].
For most animals that did not live a normal life span, the
single intratumoral injection missed a portion of the tumor.
These geographic misses are not surprising given the
multifocal tumor growth exhibited in this model and the
inability to precisely target the single injection of DTI-015 by
simply using the same stereotactic coordinates that were
used for implanting the tumor. In this regard, the tumor often
did not grow exclusively at the site of drug injection, but
instead grew as multiple foci. Histology indicated that often
an upper tumor foci was eliminated by the treatment,
whereas the injection missed a bottom foci. The use of MR
guidance should improve injection targeting. In fact, diffusion
MRI is currently being evaluated for its potential to guide
targeted delivery by mapping the spatial distribution of DTI-
015 antitumor activity in gliomas.
Although rat intracranial tumors comprise standard
models for preclinical efficacy evaluation, their accuracy in
predicting activity in humans is limited by their small size,
and substantial differences in biology and growth pattern
(e.g., lack of infiltration). The issue of size is a particularly
Figure 2. T9 gliosarcoma 7 days (A ), 9 days (B ), and 17 days (C ) postimplantation in untreated rats ( hematoxylin and eosin –stained ).
Figure 3. T9 gliosarcoma 14 days postintratumoral ethanol vehicle injection
(hematoxylin and eosin–stained ).
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troublesome problem in predicting the potential of local and
intratumoral delivery technologies because a major limitation
of these methods has been their inability to deliver effica-
cious drug levels over clinically relevant distances.
Our approach to solving the problem of limited perfusion
distance following local / intratumoral injection has been to
develop the technology of SFP. In SFP, water -miscible
organic solvent vehicles (possessing no electrical charge,
molecular weight of less than 1000 Da, and partition
coefficient of at least 0.1) are utilized to drive the pene-
tration of anticancer agents rather than standard aqueous
vehicles. Such vehicles move readily through both the
aqueous and membranous components of the tumor pro-
viding a thorough saturation of all tumor compartments by
the solubilized anticancer agent. That DTI-015 produces
efficacious levels of BCNU over centimeter distances fol-
lowing a single injection is supported by its efficacy in large
Walker subcutaneous tumors [32], its activity in human
brain and liver tumors [9,11,27], and by measurements of
DNA adducts in biopsy specimens taken from human brain
tumors treated with DTI-015 (Bodell, in preparation) [2,12].
Conclusion
We have demonstrated that BCNU, when formulated into
DTI-015 and delivered intratumorally, produces a 40% cure
rate in T9 intracranial gliosarcoma. We hypothesize that the
remarkable efficacy demonstrated in this model, coupled
with the activity profile demonstrated in early clinical testing
of DTI-015 [2,9,10,11], signals the beginning of a sig-
nificant advance in the treatment of brain tumors. Of
course, this hypothesis can only be definitively tested by
employing adequate and well -controlled randomized pro-
spective clinical trials.
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